In:
Immunotherapy, Future Medicine Ltd, Vol. 9, No. 10 ( 2017-09), p. 797-804
Abstract:
Background: Immune checkpoint inhibitors are novel cancer therapies associated with numerous autoimmune toxicities, some of which are only now being appreciated. Case presentation: A 67-year old female with metastatic cholangiocarcinoma and no prior history of diabetes was treated with leucovorin, fluorouracil, oxaliplatin and pembrolizumab. After eight cycles, she developed new onset type 1 diabetes mellitus with positive glutamic acid decarboxylase antibody titers. Conclusions: To our knowledge, this is the first reported case of PD-1 inhibitor associated Type 1 diabetes mellitus in a patient with cholangiocarcinoma and supports others’ experiences that PD-1 inhibition can cause a spectrum of autoimmune adverse events that require clinical monitoring and periodic screenings.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2017-0042
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2017